Hospital Universitario de Gran Canaria Doctor Negrin

Las Palmas de Gran Canaria 35010

4 studies enrolling now · 12 studies all time

What they study most

Acute Kidney Injury (AKI), Acute Myeloid Leukemia, Chronic Graft-versus-host-disease, Essential Thrombocythemia, Hidradenitis Suppurativa (HS), Mild Thrombocytopenia, Moderate Thrombocytopenia, Myelofibrosis, Plaque Psoriasis, Prurigo Nodularis, Psoriasis

Studies at this site

• A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease — Recruiting now
• A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia — Recruiting now
• A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa — Recruiting now
• A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia — Recruiting now
• Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) — Completed
• A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period — Completed
• A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis — Completed
• Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated — Stopped early
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• Observational Study to Evaluate the Epidemiology of Surgical-induced Acute Kidney Injury — Completed
• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib — Status unconfirmed